NASDAQ:SKYE Skye Bioscience Q1 2026 Earnings Report $1.60 -0.01 (-0.62%) Closing price 10/1/2026 03:59 PM EasternExtended Trading$1.58 -0.02 (-1.44%) As of 10/1/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Skye Bioscience EPS ResultsActual EPS-$2.56Consensus EPS -$2.32Beat/MissMissed by -$0.24One Year Ago EPSN/ASkye Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASkye Bioscience Announcement DetailsQuarterQ1 2026Date5/11/2026TimeAfter Market ClosesConference Call DateMonday, May 11, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Skye Bioscience Earnings HeadlinesSkye Bioscience (NASDAQ:SKYE) Stock: Insider 5Am Partners Vii, Llc Sells 28,700 SharesSeptember 26, 2026 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Stock: Insider 5Am Partners Vii, Llc Sells 119,379 SharesSeptember 26, 2026 | americanbankingnews.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need. | Investors Alley (Ad)Skye Bioscience (NASDAQ:SKYE) Stock: Insider Andrew Schwab Sells 119,379 SharesSeptember 26, 2026 | americanbankingnews.comIl direttore di Skye Bioscience Andrew Schwab vende azioni per $239.555September 25, 2026 | it.investing.comInsider Selling: Skye Bioscience (NASDAQ:SKYE) Major Shareholder Sells $64,733.72 in StockSeptember 21, 2026 | americanbankingnews.comSee More Skye Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email. Email Address About Skye BioscienceSkye Bioscience (NASDAQ:SKYE) is a clinical-stage biopharmaceutical company focused on developing medicines that modulate the endocannabinoid system, a network involved in metabolism, inflammation and other physiological processes. The company’s research is centered on therapies designed to influence cannabinoid receptors outside the central nervous system, with the goal of addressing disease while avoiding certain side effects associated with earlier centrally acting cannabinoid drugs. Skye’s lead investigational product is nimacimab, a monoclonal antibody that targets the cannabinoid receptor 1 (CB1). The company is evaluating nimacimab in metabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH), also known as metabolic dysfunction-associated steatotic liver disease in broader disease classifications. The program is intended to address metabolic dysfunction and inflammation through peripheral CB1 modulation. Historically, Skye also advanced SBI-100 Ophthalmic Emulsion, an investigational topical therapy designed to modulate CB1 signaling for ophthalmic conditions such as glaucoma. The company has since concentrated its development strategy on metabolic and inflammatory diseases. Skye is headquartered in San Diego, California, and has been led by co-founder and Chief Executive Officer Punit Dhillon.View Skye Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
